Cagrilintide

Cagrilintide is an acylated, long-acting analog of amylin, a hormone co-secreted with insulin. The protocol describes native amylin as promoting satiety, slowing gastric emptying, and reducing post-meal glucagon release—effects that collectively decrease calorie intake and improve postprandial metabolic signaling. Cagrilintide is presented as acting on central amylin receptors (notably in hindbrain regions such as the area postrema) to reduce appetite and energy intake. A key design feature is its lipid modification, which substantially extends its half-life (reported on the page as roughly 160–195 hours). This longer persistence is what enables once-weekly administration in research and clinical trial contexts. Overall, the “how it works” summary is central satiety signaling plus slowed gastric emptying, delivered in a long-acting formulation.